Archive for April, 2008
« Previous EntriesNew Abbott Kaletra® (lopinavir/ritonavir) Lower-Strength Tablet for Pediatric Use Approved in Europe
Monday, April 21st, 2008New Abbott Kaletra® (lopinavir/ritonavir) Lower-Strength Tablet for Pediatric Use Approved in Europe
Abbott announced that it has received marketing authorization from the European Commission for the new, lower-strength tablet formulation of the company’s leading HIV protease inhibitor, Kaletra® (lopinavir/ritonavir). The Kaletra tablet can be taken with or without food and does not require refrigeration. Lopinavir/ritonavir is […]
New Data Confirm Pramipexole (Mirapexin®/Sifrol®) Can Significantly Reduce Sleep Disturbance For People With Restless Legs Syndrome (RLS)
Monday, April 21st, 2008New Data Confirm Pramipexole (Mirapexin®/Sifrol®) Can Significantly Reduce Sleep Disturbance For People With Restless Legs Syndrome (RLS)
A new study has shown that pramipexole (Mirapexin®/Sifrol®) can significantly reduce sleep disturbance, often the most troublesome symptom experienced by people with Restless Legs Syndrome (RLS).1 The important finding, presented at the 60th Annual Meeting of the American Academy […]
Teva Announces Tentative Approval Of Generic Evista(R) Tablets
Monday, April 21st, 2008Teva Announces Tentative Approval Of Generic Evista(R) Tablets
Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced that the U.S. Food and Drug Administration has granted tentative approval for the Company’s Abbreviated New Drug Application (ANDA) to market its generic version of Lilly’s osteoporosis treatment Evista® (Raloxifene Hydrochloride) Tablets, 60 mg.
The brand product had annual sales of […]
Teva Announces Tentative Approval Of Generic Maxalt(R) Tablets
Monday, April 21st, 2008Teva Announces Tentative Approval Of Generic Maxalt(R) Tablets
Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced that the U.S. Food and Drug Administration has granted tentative approval for the Company’s Abbreviated New Drug Application (ANDA) to market its generic version of Merck’s migraine pain treatment Maxalt® (Rizatriptan Benzoate) Tablets, equivalent to 5 mg and 10 mg base. […]
Drug Company Coalition To Push For Looser Rules On Off-Label Marketing
Monday, April 21st, 2008Drug Company Coalition To Push For Looser Rules On Off-Label Marketing
Representatives of pharmaceutical companies are expressing support for loosening rules regarding drug companies’ ability to market medications for off-label uses, the Wall Street Journal reports (Mundy, Wall Street Journal, 4/18). According to the Journal, the drug industry has recently become concerned over a “potential regulatory […]
